ELI-007 & ELI-008

Enhancing immunotherapy for cancers with high unmet need

We’re leveraging the latest research on tumor development and progression to enhance Amphiphile (AMP)-powered immunotherapies for other aggressive diseases.

ELI-007

ELI-007 is a multivalent lymph node–targeted AMP peptide vaccine developed to target BRAF gene mutations. The BRAF gene is part of an intracellular signaling pathway that drives cell growth and division.1 BRAF mutations can lead to uncontrolled cell growth and ultimately cancer. BRAF mutations are present in multiple types of cancer, including 40% in melanoma, 9% in colorectal cancer (CRC), and 2% in lung cancer.1,2

High levels of BRAF protein expression in these tumors suggest susceptibility to T cells targeting the mutation.3 Previous research has shown a durable complete response through transfer of tumor-infiltrating lymphocytes recognizing mutated BRAF.3 By harnessing the ability to train T cells to target specific antigens, ELI-007 has the potential to generate tumor-specific immunity capable of eliminating BRAF-driven cancers.

ELI-008

ELI-008 is a multivalent lymph node–targeted AMP peptide vaccine developed to target p53 hotspot mutations. p53 is a tumor-suppressing protein that controls the cell cycle, DNA replication, and uncontrolled cell division during tumor growth.4 Mutations in the p53 protein lead to uncontrolled tumor progression and growth.4 Similar to Kristen rat sarcoma (KRAS), p53 mutations are present in a broad spectrum of cancer types, accounting for approximately 30% of solid tumors.5,6

We designed ELI-008 to target p53 hotspot mutations in solid tumor cancers, including melanoma, CRC, and non-small cell lung cancer (NSCLC).

ELI-007 and ELI-008 publications and presentations

Lymph Node Targeted AMP-peptide Vaccines Generate Functional T cell Immunity Against Mutant p53 and BRAF

Steinbuck MP, Cabana-Puig X, Palmer E, et al.
Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
Nov 1-5, 2023
San Diego, CA

A powerhouse platform built on our deep expertise of the lymph nodes and the immune system

References

  1. Owsley J, Stein MK, Porter J, et al. Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database. Exp Biol Med (Maywood). 2021;246(1):31-39. doi:10.1177/1535370220959657
  2. Yan N, Guo S, Zhang H, Zhang Z, Shen S, Li X. BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective. Front Oncol. 2022;12:863043. Published 2022 Mar 31. doi:10.3389/fonc.2022.863043
  3. Veatch JR, Lee SM, Fitzgibbon M, et al. Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma. J Clin Invest. 2018;128(4):1563-1568. doi:10.1172/JCI98689
  4. Kanapathipillai M. Treating p53 Mutant Aggregation-Associated Cancer. Cancers (Basel). 2018;10(6):154. Published 2018 May 23. doi:10.3390/cancers10060154
  5. Catalogue of Somatic Mutations In Caner. Gene TP53. May 23, 2023. Accessed October 6, 2023. https://cancer.sanger.ac.uk/cosmic/ gene/analysis?ln=TP53#tissue
  6. Statistics on tumor variants : Tumor variant prevalence by Tumor Site. TP53 Database: Statistics on Prevalent Tumor Variants. Accessed October 6, 2023. https://tp53.isb-cgc.org/prevalence_somatic_stats